The growing demand for immune checkpoint inhibitors is mainly driven by the rising incidence of lung cancer, the increasing prevalence of melanoma, and the expanding number of research studies related ...

Bristol-Myers Squibb has won FDA approval for the first ... BMS' notoriously hard to tolerate CTLA4 checkpoint inhibitor – which has been approved as a monotherapy for melanoma since 2011 ...

Checkpoint Therapeutics’ late entry into the PD-1/PD-L1 inhibitor category, cosibelimab, just got knocked back even further after it was turned down by the FDA as a treatment for skin cancer.

Predicting how cancer patients will respond to treatment remains a critical challenge. Immune checkpoint inhibitors (ICIs), a ...

GU ASCO annual meeting featured a session on the ABCs of antibody drug conjugates and a presentation by Dr. Di Maria Jiang discussing the targeting of bladder cancer with antibody drug conjugates. Dr.

The FDA has approved an oral, small molecule MEK inhibitor for adult and pediatric patients 2 years of age and older with neurofibromatosis type 1 who have symptomatic plexiform neurofibromas not ...

Alogliptin (NESINA), a dipeptidyl peptidase IV (DPP-4) inhibitor, was approved by the FDA on January 25 ... and impact on immune function await longer-term trials, to date, this agent appears ...

San Francisco, US Tuesday, February 18, 2025, 09:00 Hrs [IST] ...

An investigational therapy significantly shrank lung cancer tumors that are notoriously resistant to treatment by encouraging ...

FDA approval was based on two Phase III studies (NCT05072080 and NCT05349617) that demonstrated a strong immune response. The vaccine induced neutralising antibodies in up to 97.8% of 3,500 ...